Oluwadara Coker

This study shows that KRASG12C inhibitors alter the surface proteome of lung cancer cells, revealing FOLR1 as a new target when combined with an antibody drug conjugate.

This study identifies ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer by analyzing proteomic changes induced by KRAS inhibition and developing an antibody drug conjugate.

This study identifies the YAP1-SDC1 axis as a driver of resistance to mKRAS inhibitors in gastrointestinal cancers and suggests targeting this axis to overcome resistance.

The paper identifies adaptive plasticity tumor (APT) cells that reduce response to MAPK inhibitors in colorectal cancer by increasing stemness and ASCL2 expression, and shows that targeting APT cells improves therapy efficacy.